OrisDX opens early access for noninvasive oral cancer test

OrisDX has launched an Early Access Program for Oro Lesion, a salivary DNA test designed to detect oral cancer earlier than standard visual exams. Dental practices can reserve no-cost sample kits now ahead of the product’s national commercial launch.

Why it matters: - Oral cancer screening still depends heavily on visual-tactile exams that can miss molecular changes before a lesion is visible. - OrisDX says Oro Lesion is designed to move detection earlier, which could help providers identify disease sooner and route patients to specialists faster. - The test could give dental practices a noninvasive tool that fits into routine hygiene visits without adding specialized equipment.

What happened: - OrisDX opened an Early Access Program for Oro Lesion on Aug. 26, 2026. - Dental practices can reserve sample collection kits at no cost for delivery when the product reaches national commercial launch. - Providers can register their office through the Oro Lesion early adopters form.

The details: - Oro Lesion uses next-generation sequencing and AI to detect somatic mutations in salivary DNA. - OrisDX says the test has 93% sensitivity and 99% specificity. - The collection process uses a painless, 2-minute swish-and-gargle saline rinse. - Samples go to a CLIA-certified lab for genomic analysis. - Providers receive results within 14 days through the Oris Bridge platform. - The workflow is designed to integrate into routine dental hygiene visits. - The company says the test requires no specialized equipment or intensive training. - OrisDX describes itself as a molecular salivary diagnostics company born from the University of Chicago. - The announcement says Oro Lesion is the first non-invasive salivary DNA test for oral cancer detection. - A cited 2021 study in Cancer reported ultrasensitive detection of tumor-specific mutations in saliva from patients with oral cavity squamous cell carcinoma.

Between the lines: - The launch positions OrisDX to sell clinicians on convenience as much as clinical performance. - The emphasis on dental hygienists reflects where oral cancer screening often begins in real-world care. - The early-access structure lets OrisDX build adoption before the broader commercial rollout.

What’s next: - Dental practices and practice owners can submit the early access form to join the program. - OrisDX says priority shipment of kits will follow ahead of the national commercial launch. - The company is using early adopters to prepare providers for routine use once the product is fully available.

The bottom line: - OrisDX is trying to make oral cancer screening faster, simpler and more molecularly precise before lesions become visible.